Table 3.

Cox model for TGFB1 and TGFBR1 polymorphisms and outcome in patients with non-muscle invasive bladder tumors.

SNP	Cases	Tumor relapse†					Progression‡
		N	HR	95%CI	p-LRT	p-trend	N	HR	95%CI	p-LRT	p-trend
TGFB1
rs1982073					0.379	0.182				0.364	0.236
TT	280	110	1.00	Ref			25	1.00	Ref
CT	375	128	0.93	0.72–1.20			34	0.96	0.57–1.61
CC	143	41	0.78	0.54–1.12			10	0.61	0.29–1.29
rs1800472					0.674	NA				0.671	NA
CC	743	256	1.00	Ref			62	1.00	Ref
CT	62	21	1.10	0.70–1.73			5	0.82	0.33–2.06
TT	0	0	NA	NA			0	NA	NA
rs1800471					0.916	0.709				0.643	NA
GG	713	247	1.00	Ref			58	1.00	Ref
CG	100	36	1.08	0.76–1.54			11	1.24	0.65–2.39
CC	6	2	1.00	0.25–4.05			0	NA	NA
TGFBR1
rs868					0.088	0.811				0.143	0.799
AA	509	174	1.00	Ref			39	1.00	Ref
AG	259	95	1.19	0.92–1.54			28	1.38	0.84–2.24
GG	26	5	0.52	0.21–1.28			1	0.33	0.04–2.41
rs928180					0.947	0.889				0.199	NA
AA	669	230	1.00	Ref			54	1.00	Ref
AG	131	47	0.99	0.72–1.36			15	1.22	0.68–2.16
GG	3	1	0.73	0.10–5.30			0	NA	NA
rs334358										0.172	0.860
GG	508	171	1.00	Ref	0.107	0.551	39	1.00	Ref
GT	267	99	1.23	0.95–1.58			28	1.33	0.82–2.17
TT	27	6	0.63	0.28–1.43			1	0.33	0.05–2.42
TGFBR1 exon 1										0.232	NA
*9A/*9A	655	249	1.00	Ref	0.363	0.922	51	1.00	Ref
*6A/*9A	142	53	1.07	0.79–1.45			17	1.31	0.75–2.30
*6A/*6A	6	1	0.33	0.05–2.39			0	NA	NA

^†Adjusted for gender, stage-grade, tumor size, number of tumors and treatment

^‡Adjusted for stage-grade and tumor site

NA, not applicable